Niagen Bioscience, Inc NT 10-Q, filed May 12, 2020
Niagen Bioscience, Inc. (NAGE)
NT 10-Q
2020-05-12
For: 2020-03-31
View Original
Added on
October 25, 2026
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
12b-25
Commission
File Number: 001-37752
CUSIP
Number: 171077407
NOTIFICATION
OF LATE FILING
For Period Ended:
March 31,
2020
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
☐
Transition Report on Form N-SAR
☐
For the Transition Period Ended:
|
Read Instruction (on back page) Before Preparing Form. Please Print
or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained
herein.
|
If the
notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification
relates:
|
PART I -- REGISTRANT INFORMATION
|
|
ChromaDex Corporation
Full
Name of Registrant
|
|
Cody Resources, Inc.
Former
Name if Applicable
|
|
10900 Wilshire Blvd. Suite 600
Address
of Principal Executive Office (Street and Number)
|
|
Los Angeles, California 90024
City,
State and Zip Code
|
PART II -- RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or
expense and the Registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if
appropriate.)
|
|
(a) The
reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense;
|
|
☒
|
(b) The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date;
and
|
|
|
(c) The
accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
|
PART III -- NARRATIVE
State
below in reasonable detail why the Forms 10-K, 20-F, 11-K, 10-Q,
10-D, N-SAR, N-CSR or the transition report portion thereof could
not be filed within the prescribed time period.
ChromaDex
Corporation (the “Company”) has experienced unexpected
delays in the filing of its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2020 (the “Form 10-Q”) within
the prescribed time period. The compilation, dissemination and
review of the information required to be presented in the Form 10-Q
for the relevant period has imposed time constraints that could not
be eliminated that have rendered timely filing of the Form 10-Q
impracticable without unreasonable effort or expense. The
registrant undertakes the responsibility to file such quarterly
report no later than five days after its original due
date.
PART IV-- OTHER INFORMATION
(1)
Name and telephone
number of person to contact in regard to this
notification
|
Kevin
M. Farr
(Name)
|
310
(Area
Code)
|
388-6706
(Telephone
Number)
|
(2)
Have all other
periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify
report(s).
Yes☒
No
☐
(3)
Is it anticipated
that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or
portion thereof?
Yes
☐
No ☒
If so, attach
an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
ChromaDex
Corporation
|
|
(Name
of Registrant as Specified in Charter)
|
has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date: May 12,
2020
|
By:
|
/s/ Kevin M.
Farr
|
|
|
|
Name: Kevin M.
Farr
|
|
|
|
Title: Chief Financial
Officer
|